47 completed. 47 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 47 |
| Phase 2 | 5 | Completed 5 |
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors ELI-002 2P - Minimal Residual Disease, KRAS G12D | Phase 1 | Completed | Elicio Therapeutics | 25 | 2021-10-04 | 2025-09-05 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor Andes-1537 for Injection - Tumor, Solid, Gall Bladder Cancer | Phase 1 | Completed | Andes Biotechnologies | 67 | 2019-04-26 | 2022-02-24 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Merestinib, Cisplatin, Gemcitabine - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 19 | 2017-02-03 | 2020-05-19 |
| ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers Acelarin, Cisplatin - Biliary Tract Cancer, Gallbladder Cancer | Phase 1 | Completed | The Christie NHS Foundation Trust | 21 | 2016-01-01 | 2023-05-17 |
| Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder DKN-01, gemcitabine, cisplatin - Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder | Phase 1 | Completed | Leap Therapeutics, Inc. | 51 | 2015-06-01 | 2025-08-03 |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride - Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma | Phase 1 | Completed | University of Chicago | 50 | 2014-12-01 | 2023-05-31 |
| Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate Cefotetan - Cholecystitis | Phase 1 | Completed | Chonbuk National University Hospital | 529 | 2014-04-01 | 2021-01-27 |
| Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study Indocyanine Green (ICG), Near Infrared Fluorescence Cholangiography (NIRF-C) - Acute Cholecystitis, Acute Cholangitis | Phase 1 | Completed | Ohio State University | 6 | 2013-07-01 | 2014-11-03 |
| ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer ADH-1, Cisplatin, Gemcitabine Hydrochloride - Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 1 | Completed | University of Nebraska | 17 | 2013-04-09 | 2023-12-28 |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies oxaliplatin, irinotecan hydrochloride, leucovorin calcium - Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder | Phase 1 | Completed | University of Chicago | 79 | 2012-03-26 | 2020-05-08 |
| ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer selumetinib, gemcitabine, cisplatin - Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 1 | Completed | University College, London | 13 | 2012-02-01 | 2016-05-13 |
| Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin - Extrahepatic Bile Duct Cancer, Gallbladder Cancer | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 28 | 2009-11-01 | 2017-07-02 |
| Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer fluorouracil, irinotecan hydrochloride, leucovorin calcium - Anal Cancer, Carcinoma of the Appendix | Phase 1 | Completed | Mayo Clinic | 7 | 2008-06-01 | 2017-05-25 |
| Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones CE-326,597, Placebo - Obesity | Phase 1 | Completed | Pfizer | 41 | 2008-01-01 | 2010-01-18 |
| Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. PSMA/PRAME - Ovarian, Melanoma | Phase 1 | Completed | Mannkind Corporation | 12 | 2007-02-01 | 2010-08-03 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
Showing 20 of 47. Sign in to see all of them.
Gallbladder Neoplasms (44) · Pancreatic Neoplasms (34) · Stomach Neoplasms (33) · Bile Duct Neoplasms (30) · Colonic Neoplasms (26) · Rectal Neoplasms (23) · Carcinoma, Hepatocellular (22) · Esophageal Neoplasms (19) · Anus Neoplasms (15) · Breast Neoplasms (15) · Neoplasms (15) · Appendiceal Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (13) · Salivary Gland Neoplasms (12) · Carcinoma, Ovarian Epithelial (11)
Biliary Tract Diseases (47) · Digestive System Diseases (47) · Digestive System Neoplasms (44) · Neoplasms by Site (44) · Biliary Tract Neoplasms (40) · Endocrine Gland Neoplasms (38) · Endocrine System Diseases (38) · Gastrointestinal Diseases (35) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (35) · Pancreatic Diseases (34) · Adenocarcinoma (33) · Carcinoma (33) · Gastrointestinal Neoplasms (33)
Gemcitabine (9) · Cisplatin (7) · Oxaliplatin (7) · Irinotecan (6) · Leucovorin (6) · Fluorouracil (5) · Capecitabine (4) · Radiotherapy (4) · Erlotinib Hydrochloride (3) · Interleukin-12 Subunit p35 (3) · Carboplatin (2) · Cyclophosphamide (2) · Trastuzumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1)
National Cancer Institute (NCI) (6) · Memorial Sloan Kettering Cancer Center (3) · City of Hope Medical Center (2) · NYU Langone Health (2) · National Institutes of Health Clinical Center (CC) (2) · TransThera Sciences (Nanjing), Inc. (2) · University of Chicago (2) · University of Nebraska (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Andes Biotechnologies (1) · Anne Noonan (1) · Case Comprehensive Cancer Center (1) · Chonbuk National University Hospital (1) · Duke University (1)
United States (39) · United Kingdom (2) · Chile (1) · China (1) · Japan (1) · Sweden (1)
Franco M. Muggia, MD (2) · Herbert K. Lyerly, MD (2) · Jean L Grem, MD (2) · Anders Johnsson, MD, PhD (1) · Anne M Noonan, MBBChBAO, MSc (1) · Anthony W. Tolcher, MD (1) · Bernadita Mendez, PhD (1) · Bert H. O'Neil, MD (1) · Daniel H. Sterman, MD (1) · David R. Spriggs, MD (1) · Emil Lou, MD, PhD (1) · Eva Szabo, MD (1) · George Somlo, MD (1) · Hedy Kindler (1)
PMID 12196376, PMID 12393999, PMID 18470481, PMID 19023677, PMID 20068553, PMID 20179219, PMID 26912134, PMID 32878766, PMID 33142018, PMID 33210382, PMID 34499416, PMID 38195752, PMID 40315882, PMID 40673842, PMID 40790272
P30CA016087 (2), P30CA033572 (2), P30CA036727 (2), P30CA068485 (2), 2015 (1), P30CA013330 (1), P30CA014599 (1), P30CA015083 (1), P30CA016086 (1), P30CA016672 (1), P30CA043703 (1), P30CA044579 (1), P50CA127297 (1), R21CA094523 (1), U01CA076576 (1)